<DOC>
	<DOCNO>NCT02316938</DOCNO>
	<brief_summary>CRAD001AAU13 substudy CRAD001A2433 . The core study CRAD001A2433 2-year , randomize , multicenter , open-label , 2-arm study evaluate graft function everolimus reduce CNI versus MPA standard CNI adult de novo renal transplant recipient . Patients study may use cyclosporine tacrolimus CNI .</brief_summary>
	<brief_title>Assessing DSA Formation , Diabetes , Viral Infections , Structural Kidney Changes With Everolimus-based Regimen ( ADVISE )</brief_title>
	<detailed_description>Patients enrol core study CRAD001A2433 Australia eligible recruitment CRAD001AAU13 . These patient undergo additional test ( include 4 kidney allograft biopsy ) part substudy conduct core study CRAD001A2433 visit . At Day 0 ( day transplant /TX ) , Month 2 , Month 12 Month 24 additional sample ( serum , whole blood kidney biopsy ) take purpose substudy .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>1 . Currently randomize study CRAD001A2433 . 2 . Written inform consent CRAD001AAU13 must obtain assessment perform 1 . Patients investigator believe perform protocol require biopsy place patient unacceptable level risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>kidney transplant , renal transplant , biopsy , biopsy , donor specific antibody</keyword>
</DOC>